Overview

A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects

Status:
Completed

Trial end date:
2009-09-25

Target enrollment:

Participant gender:

Summary

This study will be the first repeat dose administration of GSK1322322 to investigate safety, tolerability, and pharmacokinetics in healthy subjects as well as elderly volunteer subjects. The study will also include a P450 probe drug (midazolam) to evaluate the effect of GSK1322322 to inhibit or induce CYP3A4 substrates.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Midazolam